{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:18:11Z","timestamp":1793117891264,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T00:00:00Z","timestamp":1567382400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T00:00:00Z","timestamp":1567382400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"crossref","award":["2016YFC0903400"],"award-info":[{"award-number":["2016YFC0903400"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81520108007"],"award-info":[{"award-number":["81520108007"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31471195"],"award-info":[{"award-number":["31471195"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81602258"],"award-info":[{"award-number":["81602258"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81770869"],"award-info":[{"award-number":["81770869"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Shandong Province Key Research and Development Program","award":["2018CXGC1207"],"award-info":[{"award-number":["2018CXGC1207"]}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2018ZC1053"],"award-info":[{"award-number":["ZR2018ZC1053"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Basic Application Research Plan of Qingdao","award":["15-9-1-98-jch"],"award-info":[{"award-number":["15-9-1-98-jch"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13075-019-1976-x","type":"journal-article","created":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T14:09:38Z","timestamp":1567433378000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort"],"prefix":"10.1186","volume":"21","author":[{"given":"Nan","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingshu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixia","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aichang","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinjiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4622-3731","authenticated-orcid":false,"given":"Changgui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,2]]},"reference":[{"issue":"11","key":"1976_CR1","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/nrrheum.2015.91","volume":"11","author":"CF Kuo","year":"2015","unstructured":"Kuo CF, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015;11(11):649\u201362.","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"1976_CR2","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/ar2952","volume":"12","author":"N Busso","year":"2010","unstructured":"Busso N, So A. Mechanisms of inflammation in gout. Arthritis Res Ther. 2010;12(2):206.","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"1976_CR3","doi-asserted-by":"publisher","first-page":"e114259","DOI":"10.1371\/journal.pone.0114259","volume":"9","author":"J Wang","year":"2014","unstructured":"Wang J, Qin T, Chen J, et al. Hyperuricemia and risk of incident hypertension: a systematic review and meta-analysis of observational studies. PLoS One. 2014;9(12):e114259.","journal-title":"PLoS One"},{"key":"1976_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.biochi.2015.06.025","volume":"116","author":"WG Lima","year":"2015","unstructured":"Lima WG, Martins-Santos ME, Chaves VE. Uric acid as a modulator of glucose and lipid metabolism. Biochimie. 2015;116:17\u201323.","journal-title":"Biochimie."},{"issue":"6","key":"1976_CR5","doi-asserted-by":"publisher","first-page":"e39738","DOI":"10.1371\/journal.pone.0039738","volume":"7","author":"Y Zhou","year":"2012","unstructured":"Zhou Y, Fang L, Jiang L, et al. Uric acid induces renal inflammation via activating tubular NF-kappaB signaling pathway. PLoS One. 2012;7(6):e39738.","journal-title":"PLoS One"},{"key":"1976_CR6","doi-asserted-by":"publisher","first-page":"852954","DOI":"10.1155\/2014\/852954","volume":"2014","author":"L Billiet","year":"2014","unstructured":"Billiet L, Doaty S, Katz JD, Velasquez MT. Review of hyperuricemia as new marker for metabolic syndrome. ISRN Rheumatol. 2014;2014:852954.","journal-title":"ISRN Rheumatol"},{"issue":"4","key":"1976_CR7","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1136\/annrheumdis-2014-205252","volume":"74","author":"LE Clarson","year":"2015","unstructured":"Clarson LE, Hider SL, Belcher J, Heneghan C, Roddy E, Mallen CD. Increased risk of vascular disease associated with gout: a retrospective, matched cohort study in the UK clinical practice research datalink. Ann Rheum Dis. 2015;74(4):642\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1976_CR8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29\u201342.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1976_CR9","first-page":"324","volume":"55","author":"H Yamanaka","year":"2012","unstructured":"Yamanaka H, Metabolism TG. Essence of the revised guideline for the management of hyperuricemia and gout. Japan Med Assoc J. 2012;55(4):324\u20139.","journal-title":"Japan Med Assoc J"},{"issue":"2","key":"1976_CR10","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1136\/annrheumdis-2013-203325","volume":"73","author":"F Sivera","year":"2014","unstructured":"Sivera F, Andres M, Carmona L, et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis. 2014;73(2):328\u201335.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1976_CR11","doi-asserted-by":"publisher","first-page":"58","DOI":"10.7326\/M16-0570","volume":"166","author":"A Qaseem","year":"2017","unstructured":"Qaseem A, Harris RP, Forciea MA. Management of acute and recurrent gout: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2017;166(1):58\u201368.","journal-title":"Ann Intern Med"},{"issue":"8","key":"1976_CR12","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","volume":"46","author":"KM Jordan","year":"2007","unstructured":"Jordan KM, Cameron JS, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology. 2007;46(8):1372\u20134.","journal-title":"Rheumatology"},{"issue":"3","key":"1976_CR13","first-page":"235","volume":"56","author":"Diseases M-DETFoHaIR","year":"2017","unstructured":"Diseases M-DETFoHaIR. Chinese multi-disciplinary consensus on the diagnosis and treatment of hyperuricemia and its related diseases. Zhonghua nei ke za zhi. 2017;56(3):235\u201348.","journal-title":"Zhonghua nei ke za zhi"},{"issue":"12","key":"1976_CR14","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1080\/15257770.2011.596496","volume":"30","author":"H Yamanaka","year":"2011","unstructured":"Yamanaka H. Japanese guideline for the management of hyperuricemia and gout: second edition. Nucleosides Nucleotides Nucleic Acids. 2011;30(12):1018\u201329.","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"4","key":"1976_CR15","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/1756-185X.13266","volume":"21","author":"KH Yu","year":"2018","unstructured":"Yu KH, Chen DY, Chen JH, et al. Management of gout and hyperuricemia: multidisciplinary consensus in Taiwan. Int J Rheum Dis. 2018;21(4):772\u201387.","journal-title":"Int J Rheum Dis"},{"issue":"4","key":"1976_CR16","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3810\/psm.2011.11.1946","volume":"39","author":"M Hamburger","year":"2011","unstructured":"Hamburger M, Baraf HS, Adamson TC 3rd, et al. 2011 recommendations for the diagnosis and management of gout and hyperuricemia. Phys Sportsmed. 2011;39(4):98\u2013123.","journal-title":"Phys Sportsmed"},{"issue":"3","key":"1976_CR17","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/art.40741","volume":"71","author":"X Wu","year":"2019","unstructured":"Wu X, Li C. Fresh perspectives on the CARES trial and the use of febuxostat in an Asian population: comment on the article by Choi et al. Arthritis Rheumatol. 2019;71(3):479\u201381.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"1976_CR18","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1136\/annrheumdis-2017-211574","volume":"77","author":"H Yamanaka","year":"2018","unstructured":"Yamanaka H, Tamaki S, Ide Y, et al. Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study. Ann Rheum Dis. 2018;77(2):270\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"4 Suppl 2","key":"1976_CR19","doi-asserted-by":"publisher","first-page":"S50","DOI":"10.1097\/RHU.0b013e31822541d0","volume":"17","author":"N Kamatani","year":"2011","unstructured":"Kamatani N, Fujimori S, Hada T, et al. Multicenter, open-label study of long-term administration of febuxostat (TMX-67) in Japanese patients with hyperuricemia including gout. J Clin Rheumatol. 2011;17(4 Suppl 2):S50\u20136.","journal-title":"J Clin Rheumatol"},{"issue":"6","key":"1976_CR20","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1007\/s10157-018-1586-y","volume":"22","author":"H Yu","year":"2018","unstructured":"Yu H, Liu X, Song Y, et al. Safety and efficacy of benzbromarone and febuxostat in hyperuricemia patients with chronic kidney disease: a prospective pilot study. Clin Exp Nephrol. 2018;22(6):1324\u201330.","journal-title":"Clin Exp Nephrol"},{"issue":"10","key":"1976_CR21","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1136\/annrheumdis-2015-208237","volume":"74","author":"T Neogi","year":"2015","unstructured":"Neogi T, Jansen T, Dalbeth N, et al. 2015 gout classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2015;74(10):1789\u201398.","journal-title":"Ann Rheum Dis"},{"issue":"6887","key":"1976_CR22","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/nature742","volume":"417","author":"A Enomoto","year":"2002","unstructured":"Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature. 2002;417(6887):447\u201352.","journal-title":"Nature."},{"issue":"4","key":"1976_CR23","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/ng.106","volume":"40","author":"V Vitart","year":"2008","unstructured":"Vitart V, Rudan I, Hayward C, et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet. 2008;40(4):437\u201342.","journal-title":"Nat Genet"},{"issue":"5","key":"1976_CR24","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1046\/j.1440-1746.2002.02692.x","volume":"17","author":"M Arai","year":"2002","unstructured":"Arai M, Yokosuka O, Fujiwara K, et al. Fulminant hepatic failure associated with benzbromarone treatment: a case report. J Gastroenterol Hepatol. 2002;17(5):625\u20136.","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"1976_CR25","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/MEG.0b013e328358ace9","volume":"25","author":"B Haring","year":"2013","unstructured":"Haring B, Kudlich T, Rauthe S, Melcher R, Geier A. Benzbromarone: a double-edged sword that cuts the liver? Eur J Gastroenterol Hepatol. 2013;25(1):119\u201321.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"4 Suppl 2","key":"1976_CR26","first-page":"S19","volume":"17","author":"N Kamatani","year":"2011","unstructured":"Kamatani N, Fujimori S, Hada T, et al. Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study. J Clin Rheumatol. 2011;17(4 Suppl 2):S19\u201326.","journal-title":"J Clin Rheumatol"},{"issue":"2","key":"1976_CR27","doi-asserted-by":"publisher","first-page":"163","DOI":"10.5414\/CP202629","volume":"55","author":"Q Zhou","year":"2017","unstructured":"Zhou Q, Su J, Zhou T, Tian J, Chen X, Zhu J. A study comparing the safety and efficacy of febuxostat, allopurinol, and benzbromarone in Chinese gout patients: a retrospective cohort study. Int J Clin Pharmacol Ther. 2017;55(2):163\u20138.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"5","key":"1976_CR28","doi-asserted-by":"publisher","first-page":"779","DOI":"10.3109\/14397595.2015.1016257","volume":"25","author":"T Yamamoto","year":"2015","unstructured":"Yamamoto T, Hidaka Y, Inaba M, et al. Effects of febuxostat on serum urate level in Japanese hyperuricemia patients. Mod Rheumatol. 2015;25(5):779\u201383.","journal-title":"Mod Rheumatol"},{"issue":"11","key":"1976_CR29","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1111\/dom.12135","volume":"15","author":"MA Becker","year":"2013","unstructured":"Becker MA, MacDonald PA, Hunt BJ, Jackson RL. Diabetes and gout: efficacy and safety of febuxostat and allopurinol. Diabetes Obes Metab. 2013;15(11):1049\u201355.","journal-title":"Diabetes Obes Metab"},{"issue":"23","key":"1976_CR30","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1056\/NEJMoa050373","volume":"353","author":"MA Becker","year":"2005","unstructured":"Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450\u201361.","journal-title":"N Engl J Med"},{"issue":"6","key":"1976_CR31","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1111\/1756-185X.12266","volume":"17","author":"X Huang","year":"2014","unstructured":"Huang X, Du H, Gu J, et al. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia. Int J Rheum Dis. 2014;17(6):679\u201386.","journal-title":"Int J Rheum Dis"},{"issue":"4 Suppl 2","key":"1976_CR32","first-page":"S44","volume":"17","author":"N Kamatani","year":"2011","unstructured":"Kamatani N, Fujimori S, Hada T, et al. An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study. J Clin Rheumatol. 2011;17(4 Suppl 2):S44\u20139.","journal-title":"J Clin Rheumatol"},{"issue":"22","key":"1976_CR33","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1093\/eurheartj\/ehz119","volume":"40","author":"S Kojima","year":"2019","unstructured":"Kojima S, Matsui K, Hiramitsu S, et al. Febuxostat for cerebral and CaRdiorenovascular Events PrEvEntion StuDy. Eur Heart J. 2019;40(22):1778\u201386.","journal-title":"Eur Heart J"},{"issue":"1","key":"1976_CR34","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.kint.2017.04.031","volume":"93","author":"J Lu","year":"2018","unstructured":"Lu J, Hou X, Yuan X, et al. Knockout of the urate oxidase gene provides a stable mouse model of hyperuricemia associated with metabolic disorders. Kidney Int. 2018;93(1):69\u201380.","journal-title":"Kidney Int"},{"issue":"6","key":"1976_CR35","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00467-013-2549-x","volume":"29","author":"SA Fathallah-Shaykh","year":"2014","unstructured":"Fathallah-Shaykh SA, Cramer MT. Uric acid and the kidney. Pediatric Nephrol. 2014;29(6):999\u20131008.","journal-title":"Pediatric Nephrol"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-019-1976-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-019-1976-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-019-1976-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T19:34:03Z","timestamp":1598902443000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-019-1976-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,2]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1976"],"URL":"https:\/\/doi.org\/10.1186\/s13075-019-1976-x","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,2]]},"assertion":[{"value":"27 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the ethics committee of Affiliated Hospital of Qingdao University, and informed consents were obtained from all patients.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"200"}}